WO1989002268A1 - Presentation pharmaceutique potentialisant l'effet cytotrophique des serums et/ou des anticorps antitissus animaux et/ou humains - Google Patents
Presentation pharmaceutique potentialisant l'effet cytotrophique des serums et/ou des anticorps antitissus animaux et/ou humains Download PDFInfo
- Publication number
- WO1989002268A1 WO1989002268A1 PCT/FR1988/000454 FR8800454W WO8902268A1 WO 1989002268 A1 WO1989002268 A1 WO 1989002268A1 FR 8800454 W FR8800454 W FR 8800454W WO 8902268 A1 WO8902268 A1 WO 8902268A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- medicament according
- antibodies
- sera
- air
- solvent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
Definitions
- the cytotrophic effect of sera and / or anti-tissue antibodies on the homologous tissue is well known.
- SAL heterologous antilymphocyte serum
- the best route is therefore that which allows the greatest possible contact surface to be obtained between the remedy and the tissue chosen as the route of penetration of this remedy.
- a spray bottle fitted with a mechanical pump avoiding the use of a propellant gas.
- a means of mechanical dispersion for example: vaporizers, fumigators or "atomizers", nebulizers.
- the mechanical pressure valve system will be used, for example.
- a gaseous complex medium it is possible to use the mixture of air with gases such as nitrogen, fluorinated polyhalogenated hydrocarbons, fluorocarbons, chlorofluorocarbons, fluoroalkanes, ether-oxides, dimethyl ether compounds, carbon dioxide, light hydrocarbons, butane, isobutane, propane, nitrous oxide.
- liquid phase and the gas phase of these "aerosols" can be obtained by spraying into the air using a propellant and a sealed bottle fitted with a valve and a nozzle, the active principle (s) dissolved beforehand in a solvent, the propellant itself being constituted sometimes by nitrogen under pressure, sometimes by a liquid originating for example from the liquefaction under low pressure of hydrocarbons.
- the drug substance can be dissolved in all possible solvents taking into account the technique used, such as by way of non-limiting examples sodium mercurothiolate, surfactants, thiomucase, alcohols, glycerides , eucalyptol, oleic glycerides, polyethylene oleic glycerides, propylene glycol, sorbitan sesquioleate, sodium lauryl sulfate, etc.
- sodium mercurothiolate such as by way of non-limiting examples sodium mercurothiolate, surfactants, thiomucase, alcohols, glycerides , eucalyptol, oleic glycerides, polyethylene oleic glycerides, propylene glycol, sorbitan sesquioleate, sodium lauryl sulfate, etc.
- a classic dosing system suitable for aerosol presentation allows you to know the quantity administered.
- the absorption surface of the small intestine is generally estimated at 40 to 50 square meters.
- the absorption surface of the buccopharyngeal cavities is estimated at 75 square centimeters, that of the mucous membranes of the nose at 80 square centimeters.
- enteric-coated pharmaceutical presentations can be retained, whether they are in the form of capsules, capsules, cachets, tablets, pills, granules, granules, globules, microgranules, microcapsules, etc.
- a preferred embodiment consists in using all the gastroprotected forms known as “programmed release” or “delayed release” such as for example microgranules, microcapsules, matrices, tablets etc.
- microgranules can for example be manufactured by granulation of the active principle (s) (the formulas include for example: one or more bonding excipient (s) (vegetable gums)
- drying excipient cellulose, talc, starch, silica
- the support grain can for example consist of sugar, starch; fixing the active principle (s) ( s) can for example be made according to the general formula: one or more bonding excipient (s): vegetable gums, polyvinylpyrrolidone, fatty acids, ethylated or methylated cellulose, polymethyl methacrylate on the one hand and aqueous-alcoholic solvent on the other hand
- the membranes of the dosage form with programmed release microgranules can be: - of natural origin: + of the resin type (vegetable gums) + of the lipid type (fatty acids, waxes) - of synthesis: + of the polyvinyl alcohol + polyvinylpyrrolidone + cellulose + acrylic resins type
- microcapsules conventionally comprises three stages, according to the principle known to those skilled in the art of coacervation. The microgranules and microcapsules can then be distributed in gastro-resistant capsules.
- a preferred embodiment therefore consists in inserting the active principle (s) (for example by impregnation of the microgranules) in a pharmaceutical form with enteric coating, this enteric coating being able to be constituted for example: by phthalic derivatives, cellulose acetophthalate, starch acetophthalate, hydroxypropyl methylcellulose phthalate polyvinyl acetophthalate, maleic derivatives, copolymers containing maleic anhydride, acrylic derivatives, gluten, zein, formalin, gum hairspray, gastro-resistant fatty excipients, Carnauba wax, stearic acid etc.
- enteric coating being able to be constituted for example: by phthalic derivatives, cellulose acetophthalate, starch acetophthalate, hydroxypropyl methylcellulose phthalate polyvinyl acetophthalate, maleic derivatives, copolymers containing maleic anhydride, acrylic derivatives, gluten, zein, formalin, gum hairspray,
- Plasticizers for cellulose acetate phthalate may be used, by way of nonlimiting examples: castor oil, glycerin, propylene glycol, tributyl acetate citrate.
- Another variant consists in using grains, granules, globules, microcapsules, small tablets made gastroresis tants, allowing a progressive release of the active ingredients, the drugs leaving the stomach regularly according to each opening of the pylorus.
- matrices with prolonged action can be:
- -mineral for example: magnesium oxychloride, phosphate cement obtained by the action of phosphoric acid on zinc oxide and alumina, alumino-calcium cement, calcium sulfate and phosphate anhydrous calcium in the presence of water, natural mixed silicates of aluminum and magnesium, talc; to these mineral products must be added a binder, such as, for example: ethylcellulose, polyvinylpyrrolidone, zelin, colophane; the most conventional manufacturing technique for these mineral matrices being wet granulation followed compression
- -hydrophobic for example: waxes (such as beeswax), fatty acids and their esters (such as stearic acid and butyl stearate), fatty alcohols, hydrogenated oils, glycerides
- -hydrophilic for example: cellulosic polymers (such as methylcelluloses, sodium carboxymethylcelluloses, hydroxypropyimethylcelluloses), vinyl polymers (such as pclyvinylpyrrolidone, carboxyvinyl derivatives ques)
- cellulosic polymers such as methylcelluloses, sodium carboxymethylcelluloses, hydroxypropyimethylcelluloses
- vinyl polymers such as pclyvinylpyrrolidone, carboxyvinyl derivatives ques
- cellulose derivatives such as ethylcellulosic, methylcellulose, hydroxypropylmethylcellulose, cellulose acetophthalate
- acrylic derivatives vinyl derivatives.
- microencapsulation can be carried out by phase separation or simple “coacervation” (for example by using gelatin as a macromolecule intended for encapsulation and as hydrophilic agents producing coacervates: ethanol or solutions electrolytes such as sodium sulfate for example) or complex.
- Microencapsulation can also be done by polymerization or interfacial reaction or by physical and mechanical processes (for example by encapsulation by phase separation in organic medium using encapsulation polymers of ethylcellulose and nitrocellulose and as a precipitation polymer, responsible for the DROBY effect, a polybutadiene, by for example a butyl rubber; encapsulation by exchange of solvents; by inclusion in an emulsified system; by the wurster process, etc.)
- Pharmaceutical forms resulting from the formation of sparingly soluble complexes such as the complexes obtained with resins can also be used.
- a preferred embodiment for increasing this contact surface consists in associating SIMULTANE-MENT with several transmu ⁇ uous penetration pathways (for example: perlingual, pulmonary and digestive).
- the sera and / or antibodies and / or any fractions of these sera and / or of these antibodies, such as, by way of nonlimiting example, the Fc fragment of the antibodies
- the sera and / or antibodies directed against human and / or animal tissues, sera and / or antibodies used for cytotrooic purposes or cytostimulants in these dosage forms aerosols and / or "transmucosals” making it possible to reinforce the cytotrophic effect, cytostimulant sought, and this thanks to the increase, at equal dose of active principle (s), of the surface or INTERFACE of contact between these sera and / or antibody and the biological tissue (s) used for these same sera and / or antibodies for pathway (s
- These antibodies and / or sera used in the form of an aerosol. may be suspended in a complex gaseous medium composed not only of air but also by various gases such as dichlorodifluoromethane and / or trichloromonofluoromethane and / or tetrafluorodichloroethane and / or tetrafluorotrichloroethane and / or monofluorotrichloromethane and / or trifluorotrichloroethane and / or trichlorofluoromethane.
- gases such as dichlorodifluoromethane and / or trichloromonofluoromethane and / or tetrafluorodichloroethane and / or tetrafluorotrichloroethane and / or monofluorotrichloromethane and / or trifluorotrichloroethane and / or trichlorofluoromethane.
- the drug can also be suspended in the form of an aerosol, in which the solvent containing the drug substance (s) comes from the liquefaction under low pressure of polyhalogenated hydrocarbons fluorinated and / or light hydrocarbons.
- This solvent used to dissolve the drug substance (s) may contain one or more alcohol (s) and / or one or more glyceride (s) and / or eucalvptol and / or oleic glycerides and / or polyoxyethylene oleic glycerides and / or propylene glycol and / or sorbitan sesquioleate and / or sodium lauryl sulfate.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR8712797A FR2620335A1 (fr) | 1987-09-15 | 1987-09-15 | Presentation pharmaceutique potentialisant l'effet cytotrophique des serums et/ou des anticorps antitissus animaux et/ou humains |
FR87/12797 | 1987-09-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1989002268A1 true WO1989002268A1 (fr) | 1989-03-23 |
Family
ID=9354933
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1988/000454 WO1989002268A1 (fr) | 1987-09-15 | 1988-09-14 | Presentation pharmaceutique potentialisant l'effet cytotrophique des serums et/ou des anticorps antitissus animaux et/ou humains |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0354930A1 (fr) |
AU (1) | AU2423488A (fr) |
FR (1) | FR2620335A1 (fr) |
WO (1) | WO1989002268A1 (fr) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2140353A1 (de) * | 1970-08-12 | 1972-02-17 | Roussel Uclaf, Paris | Neues Proteid biologischen Ursprungs und Verfahren zu dessen Herstellung |
GB1499078A (en) * | 1975-05-29 | 1978-01-25 | Green Cross Corp | Medicinal preparations containing ypsilon-globulin |
FR2439014A1 (fr) * | 1978-10-17 | 1980-05-16 | Stolle Res & Dev | Microparticules contenant des agents therapeutiques ou medicinaux et leur application comme contraceptif |
WO1986005398A1 (fr) * | 1985-03-18 | 1986-09-25 | Pascal Berdal | Preparations pharmaceutiques immunomodulantes |
FR2584294A1 (fr) * | 1985-07-08 | 1987-01-09 | Berdal Pascal | Compositions pharmaceutiques a visee cytotrophique |
EP0209493A2 (fr) * | 1985-07-16 | 1987-01-21 | Ciba-Geigy Ag | Prophylaxie et traitement de la coqueluche |
-
1987
- 1987-09-15 FR FR8712797A patent/FR2620335A1/fr active Pending
-
1988
- 1988-09-14 AU AU24234/88A patent/AU2423488A/en not_active Abandoned
- 1988-09-14 WO PCT/FR1988/000454 patent/WO1989002268A1/fr not_active Application Discontinuation
- 1988-09-14 EP EP19880908245 patent/EP0354930A1/fr not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2140353A1 (de) * | 1970-08-12 | 1972-02-17 | Roussel Uclaf, Paris | Neues Proteid biologischen Ursprungs und Verfahren zu dessen Herstellung |
GB1499078A (en) * | 1975-05-29 | 1978-01-25 | Green Cross Corp | Medicinal preparations containing ypsilon-globulin |
FR2439014A1 (fr) * | 1978-10-17 | 1980-05-16 | Stolle Res & Dev | Microparticules contenant des agents therapeutiques ou medicinaux et leur application comme contraceptif |
WO1986005398A1 (fr) * | 1985-03-18 | 1986-09-25 | Pascal Berdal | Preparations pharmaceutiques immunomodulantes |
FR2584294A1 (fr) * | 1985-07-08 | 1987-01-09 | Berdal Pascal | Compositions pharmaceutiques a visee cytotrophique |
EP0209493A2 (fr) * | 1985-07-16 | 1987-01-21 | Ciba-Geigy Ag | Prophylaxie et traitement de la coqueluche |
Also Published As
Publication number | Publication date |
---|---|
EP0354930A1 (fr) | 1990-02-21 |
AU2423488A (en) | 1989-04-17 |
FR2620335A1 (fr) | 1989-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0385846B1 (fr) | Composition pharmaceutique à libération prolongée d'acide valproîque | |
US7611728B2 (en) | Osmotic delivery of therapeutic compounds by solubility enhancement | |
ES2307739T3 (es) | Sales farmaceuticas de compuestos 1-fenil-3-dimetilamino-propano. | |
JP3278192B2 (ja) | 徐放性液剤 | |
EP0717986B1 (fr) | Rotogranulation et enrobage d'acetaminophène, pseudoéphédrine, chlorphéniramine, et, éventuellement, dextrométhorphane | |
FR2624732A1 (fr) | Formulation pharmaceutique a liberation prolongee | |
WO2002020037A1 (fr) | Composition pharmaceutique a administration orale liberee au niveau colique | |
LU88201A1 (fr) | Compositions pharmaceutiques stabilisées comprenant un composé inhibituer de la HMG-CoA réductase et procédé pour leur préparation | |
CA2742680C (fr) | Compositions pharmaceutiques pour la liberation controlee du methylphenidate | |
WO2005070398A2 (fr) | Compositions pharmaceutiques de candesartan cilexetil stabilisees par des co-solvants | |
US20060159758A1 (en) | Coating composition for taste masking coating and methods for their application and use | |
JPS635020A (ja) | 制御放出性イブプロフエン製剤 | |
FR2735369A1 (fr) | Compositions pharmaceutiques a base de sel de sodium du diclofenac et de thiocolchicoside | |
FR2885526A1 (fr) | Medicament oral a base d'inhibiteur de pompe a protons | |
WO2005004860A2 (fr) | Nouvelle composition pharmaceutique solide comprenant de l'amisulpride | |
FR2778848A1 (fr) | Forme pharmaceutique multiparticulaire a liberation programmee et pulsee et son procede de preparation | |
EP0981340B1 (fr) | Formulations pharmaceutiques presentees sous forme seche pour l'administration orale d'un compose ammonium quaternaire cyclique | |
US6521262B2 (en) | Solid instant-release forms of administration and process for producing the same | |
KR101506626B1 (ko) | 아세브로필린 및 소수성 서방기제를 포함하는 서방형 약학 조성물 | |
FR2831446A1 (fr) | Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire | |
WO1989002268A1 (fr) | Presentation pharmaceutique potentialisant l'effet cytotrophique des serums et/ou des anticorps antitissus animaux et/ou humains | |
BE900824A (fr) | Composition de comprimes. | |
WO2022200402A1 (fr) | Formulation par voie orale d'ivermectine et utilisations | |
NZ207768A (en) | Sustained release tablets comprising dipyridamole | |
EP0908177B1 (fr) | Procédé pour former des compositions pharmaceutiques de bromazépam sous forme de granules ou pilules sphériques à action controlée et soutenue et compositions pharmaceutiques obtenues par ce procédé |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR CH DE DK FI GB HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BJ CF CG CH CM DE FR GA GB IT LU ML MR NL SE SN TD TG |
|
WWP | Wipo information: published in national office |
Ref document number: 1988908245 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1988908245 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1988908245 Country of ref document: EP |